CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CUV - CLINUVEL PHARMACEUTICALS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX300 | ALL-ORDS
Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$19.39
20 Mar |
OPEN $20.38 |
HIGH $20.58 |
90,760 LOW $19.35 |
-0.930| OTHER COMPANIES IN THE SAME SECTOR | |||
| ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . OCC . ACW . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . MAP . CAU . OPT . ANP . TRP . BIO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 06/09 - ex-div 4c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | 42.3 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 4.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 65.7 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 254.1 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 39.9 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 31.77 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 18.62 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 18.45 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | 16.48 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | 18.62 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 29.17 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 38.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CUV STOCK CHART
FNArena News on CUV
| 1 |
Australian Broker Call *Extra* Edition – Mar 08, 2023Mar 08 2023 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Feb 10, 2023Feb 10 2023 - Daily Market Reports |
| 3 |
In Brief: Insurers, Healthcare, Contractors, Classifieds, RetailDec 09 2022 - Weekly Reports |
| 4 |
The Short Report – 29 Sep 2022Sep 29 2022 - Weekly Reports |
| 5 |
Australian Broker Call *Extra* Edition – Sep 28, 2022Sep 28 2022 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 4 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
| 5 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
| 6 |
Dr Boreham’s Crucible: Inoviq LtdSep 19 2022 - Small Caps |
| 7 |
CSL: Offering Buying OpportunitySep 13 2022 - Technicals |
| 8 |
Dr Boreham’s Crucible: Vaxxas Pty LtdSep 07 2022 - FYI |
| 9 |
Dr Boreham’s Crucible: Telix PharmaceuticalsAug 22 2022 - Small Caps |
| 10 |
Dr Boreham’s Crucible: OrthocellJul 26 2022 - Small Caps |
